Cleveland Clinic reveals top 10 medical innovations for 2022

Tops the list of next-generation mRNA vaccinologists.

CLEVELAND – As the evolution of medicine continues to move forward, a team of clinic clinic experts has compiled a list of “Top 10 Medical Innovations for 2022”.

How was the list determined?

“Breakthrough Technologies” was compiled by a commission of experts on the Cleveland Clinic. The effort was led by Dr. D. Jeffrey Vince, who is the Executive Director of Innovation and the Department of Biomedical Engineering at the Cleveland Clinic.

Related: Cleveland Clinic performed more than 1,000 organ transplants in 2021, up 18% from the previous year

“In order to take the desired place in the list of the top 10, innovations are undergoing a rigorous selection process,” – said representatives of the Cleveland Clinic. “Each year, our team interviews nearly 100 Cleveland Clinic leaders to nominate more than 150 nominations, which are collected and reviewed by an established committee.

The following criteria are also taken into account:

  • The innovation should have a significant clinical impact and bring certain benefits to patients over existing practices (improved outcomes, lower costs, meeting unmet needs, etc.).
  • The innovation should have a high probability of widespread ecosystem health next year.
  • If applicable, the innovation should be in clinical trials or come out of them with published best results and a high probability of approval / clearance next year.
  • An innovation should have a significant human interest in its application or benefits.

Related: Cleveland Clinic’s plans for 2022 set out in a report on the state of the clinic from CEO Tom Mikhalevich

“At the Cleveland Clinic, a shared passion for superior service and an established culture of innovation contribute to an ongoing dialogue to improve health care between our clinicians and researchers,” said Dr. Vince. “That’s why our experts are always keeping an eye on the pulse of new technologies that should change the face of healthcare. A program of the 10 Best Medical Innovations has been launched to share its views with the wider healthcare community, and year after year our experts continue to successfully predict progress in devices, technologies, topics and therapies. ”

Here is a list of them in order of expected importance for 2022:

Vaccinology of the next generation of mRNA

Advances in the creation, purification, and cellular delivery of RNA have made it possible to develop mRNA vaccines for a wide range of applications, such as cancer and Zika virus infection. The technology is cost-effective, relatively easy to manufacture, and evokes immunity in a new way. In addition, the advent of the COVID-19 pandemic has demonstrated that the world needs the rapid development of a vaccine that could be deployed around the world. Thanks to previous research that laid the groundwork for this technology, an effective vaccine against COVID-19 has been developed, manufactured, approved and deployed in less than a year. This landscape-changing technology can be used to quickly and effectively treat some of the most serious health diseases.

PSMA-targeted therapy for prostate cancer

Each year, more than 200,000 American men are diagnosed with prostate cancer, making it the most commonly diagnosed cancer among men in the United States. Accurate imaging is crucial for tumor localization, disease staging, and recurrence detection. PSMA, an antigen that is found at high levels on the surface of prostate cancer cells, is a potential biomarker of the disease. The PET scan of PMSA uses a radioactive marker to attach to PSMA proteins, which are then combined with CT or MRI to visualize the location of prostate cancer cells. In 2020, this technology received FDA approval based on phase III clinical trials that showed significantly increased accuracy in detecting prostate cancer metastases compared to conventional bone and CT imaging. In the early detection of PSMA by PET scan, recurrent prostate cancer can be treated with a targeted approach using stereotoxic radiation therapy of the body, surgery and / or systemic therapy on an individual basis.


It is known that high blood cholesterol, especially low-density lipoprotein (LDL-C), is a significant factor in the development of cardiovascular disease. In 2019, the FDA reviewed an application for inclusion in the treatment of primary hyperlipidemia in adults with elevated LDL cholesterol levels during statin therapy at the maximum tolerated dose. Inclisiran is an injectable small interfering RNA that targets the PCSK9 protein. Unlike statins, it requires infrequent intake (twice a year) and provides an effective and sustained reduction in LDL-C in combination with statins. Its long-term effect can help alleviate medication failure, which is a major cause of unsuccessful cholesterol lowering. Inclisiran was approved by the FDA in December 2021 and is widely considered variable for patients with heart disease.

NEW Drug for the treatment of type 2 diabetes

In the United States, every 10th person has diabetes, which affects how the body processes food into energy. One of the potential therapies is injectable injectable once a week dual glucose-dependent insulinotropic polypeptide (GIP) and a glucagon-like peptide (GLP-1) receptor agonist that aims to control blood sugar. Subcutaneous GLP-1 and GIP receptors cause the pancreas to release insulin and block the hormone glucagon, limiting blood sugar spikes after a meal. In addition, it slows down digestion, causing people to stay full longer and eat less. So far, late phase III clinical trials have shown that treatment significantly reduces hemoglobin A1C levels in type 2 diabetes and promotes weight loss, making it potentially the most effective therapy for diabetes and obesity.


Experts believe that the level of postpartum depression may be at least twice as high as current statistics show, because many cases remain undiagnosed. Currently, counseling and antidepressants are the main treatments, but some women do not respond to these treatments. In 2019, the FDA approved intravenous infusion treatment specifically for the treatment of postpartum depression. This new therapy, which is carried out around the clock for 60 hours, uses neurosteroids to control the brain’s response to stress.

This treatment design is groundbreaking because it focuses on signaling that is considered deficient in postpartum depression sensitive to hormones. In addition, this treatment benefits very quickly, while traditional antidepressants usually take two to four weeks to have a significant effect. This quick treatment option would be a breakthrough for women with this often-ignored disease.

Targeted drugs for hypertrophic cardiomyopathy

For decades, clinicians have been able to treat the symptoms of hypertrophic cardiomyopathy (HCMP) in patients with limited effectiveness using drugs designed to treat other heart conditions. Currently, nonspecific drugs are prescribed to treat some symptoms of HCMP with other cardiovascular diseases. These treatments include beta-blockers, antiarrhythmic drugs, calcium channel blockers and anticoagulants. However, the new treatment helps reduce the root cause of the problem in many patients. The first-in-class drug specifically targets the heart muscle to reduce abnormal contractions caused by genetic variants that cause the heart to overload. By acting on this mechanism in patients with HCM, this new treatment not only improves symptoms and quality of life, but can potentially slow disease progression. The FDA has set a target expiration date for this therapy on April 28, 2022. If approved, it will be the first drug clearly designed to treat HCMP and gives new hope to patients and physicians.


More than 50 percent of all menopausal women experience hot flashes that can last an average of seven years. Although hormone therapy is effective and safe when used properly, it involves some risk, and not all patients are suitable candidates or willing to try this treatment option. Fortunately, a new group of non-hormonal drugs, called NK3R antagonists, has emerged as a viable alternative to hormone therapy. These drugs disrupt the signaling pathway in the brain that has been associated with the development of hot flashes and have shown promising effects in clinical trials to alleviate moderate and severe hot flashes at menopause as effectively as hormones. Although further research is needed to fully understand the efficacy and safety of these new drugs, it is clear that the next generation of non-hormonal treatments for menopausal hot flashes is already on the horizon.

IMPLANTATION in severe paralysis

About every 50 Americans, or 5.4 million people, have some form of paralysis. Most patients experience a significant reduction in overall health. Recently, the team gave new hope to these patients, using implantable brain-computer interface technology to restore lost motor movement and allow patients to control digital devices. The technology uses implanted electrodes to collect motion signals from the brain and decode them into motion commands. It has been shown to restore arbitrary motor impulses in patients with severe paralysis due to brain, spinal cord, peripheral nerves, or muscle dysfunction. Although the interface technology is in its infancy, the FDA has recognized the implanted “breakthrough device”, reinforcing the need to move this technology to the bed of patients who need it most.


Sepsis is a serious inflammatory reaction to infection and a major cause of hospitalization and death worldwide. Because septic shock has a very high mortality rate, early diagnosis of sepsis is crucial. Diagnosis can be difficult because early symptoms are common to other diseases, and the current standard of diagnosis is nonspecific. Artificial intelligence (AI) has emerged as a new tool that can help detect sepsis quickly. Using AI algorithms, the tool detects several key risk factors in real time by monitoring patients ’electronic medical records as input to physicians. Assessing high-risk patients can help facilitate early intervention, which can improve outcomes, reduce health care costs and save lives.


Often referred to as a “silent killer,” hypertension or high blood pressure are usually asymptomatic, with an increased risk of serious health problems including heart disease, heart failure, and stroke. There are effective treatment options; however, many adults are unaware that they have hypertension until they experience a significant health crisis. By using machine learning, a type of artificial intelligence, doctors can better select more effective medications, drug combinations, and dosages to improve hypertension control. AI will also allow physicians to predict cardiovascular disease and allow physicians to focus on interventions before they occur. Prognostic analytics gives providers a key that can open the door to prevent hypertension and many other diseases.

Leave a Comment